MA30085B1 - Traitement du diabete de type 2 avec une association d'un inhibiteur de dpiv et de metformine ou d'une thiazolidinedione - Google Patents

Traitement du diabete de type 2 avec une association d'un inhibiteur de dpiv et de metformine ou d'une thiazolidinedione

Info

Publication number
MA30085B1
MA30085B1 MA31071A MA31071A MA30085B1 MA 30085 B1 MA30085 B1 MA 30085B1 MA 31071 A MA31071 A MA 31071A MA 31071 A MA31071 A MA 31071A MA 30085 B1 MA30085 B1 MA 30085B1
Authority
MA
Morocco
Prior art keywords
thiazolidinedione
metformin
diabetes
treatment
type
Prior art date
Application number
MA31071A
Other languages
English (en)
Inventor
Jonathan Rachman
Original Assignee
Prosidion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35841111&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30085(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Prosidion Ltd filed Critical Prosidion Ltd
Publication of MA30085B1 publication Critical patent/MA30085B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Traitement du diabète de type 2 avec une association d'un inhibiteur de DPIV et de metformine ou d'une thiazolidinedione La présente invention concerne une méthode thérapeutique pour la régulation de la glycémie, en particulier une méthode pour le traitement du diabète de type 2, comprenant l'administration d'un inhibiteur de DPIV conjointement avec de la metformine ou une thiazolidinedione.
MA31071A 2005-12-23 2008-06-23 Traitement du diabete de type 2 avec une association d'un inhibiteur de dpiv et de metformine ou d'une thiazolidinedione MA30085B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0526291.0A GB0526291D0 (en) 2005-12-23 2005-12-23 Therapeutic method

Publications (1)

Publication Number Publication Date
MA30085B1 true MA30085B1 (fr) 2008-12-01

Family

ID=35841111

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31071A MA30085B1 (fr) 2005-12-23 2008-06-23 Traitement du diabete de type 2 avec une association d'un inhibiteur de dpiv et de metformine ou d'une thiazolidinedione

Country Status (28)

Country Link
US (3) US20100216800A1 (fr)
EP (1) EP1965783B1 (fr)
JP (2) JP2009520801A (fr)
KR (1) KR20080080220A (fr)
CN (1) CN101365434A (fr)
AU (1) AU2006327974B2 (fr)
BR (1) BRPI0620450A2 (fr)
CA (1) CA2634379C (fr)
CY (1) CY1114401T1 (fr)
DK (1) DK1965783T3 (fr)
EA (1) EA017084B1 (fr)
ES (1) ES2427822T3 (fr)
GB (1) GB0526291D0 (fr)
HK (1) HK1121074A1 (fr)
HR (1) HRP20130880T1 (fr)
IL (1) IL192257A0 (fr)
MA (1) MA30085B1 (fr)
MX (1) MX2008008250A (fr)
NO (1) NO20082790L (fr)
NZ (1) NZ569427A (fr)
PL (1) PL1965783T3 (fr)
PT (1) PT1965783E (fr)
RS (1) RS52942B (fr)
SG (1) SG186610A1 (fr)
SI (1) SI1965783T1 (fr)
UA (1) UA100111C2 (fr)
WO (1) WO2007072083A1 (fr)
ZA (1) ZA200806200B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (fr) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Compositions d'inhibiteurs de la DPP IV
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
CN102838599A (zh) 2006-05-04 2012-12-26 贝林格尔.英格海姆国际有限公司 多晶型
EP2185138B1 (fr) 2007-07-19 2016-09-07 Takeda Pharmaceutical Company Limited Preparation solide comprenant du alogliptin et metformin chlorhydrate
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
AU2009290911A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
AU2009331471B2 (en) 2008-12-23 2015-09-03 Boehringer Ingelheim International Gmbh Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
KR102668834B1 (ko) 2009-11-27 2024-05-24 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
RU2533560C2 (ru) * 2010-03-08 2014-11-20 Цзянсу Хэнжуй Медицин Ко., Лтд. Фармацевтическая композиция для лечения диабета 2 типа
ES2935300T3 (es) 2010-05-05 2023-03-03 Boehringer Ingelheim Int Combiterapia
KR20230051307A (ko) 2010-06-24 2023-04-17 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
EA030121B1 (ru) 2011-07-15 2018-06-29 Бёрингер Ингельхайм Интернациональ Гмбх Замещенные хиназолины, их получение и их применение в фармацевтических композициях
KR20200137035A (ko) 2012-01-06 2020-12-08 앤지 파마 유에스 엘엘씨 바이구아나이드 조성물 및 대사 장애를 치료하는 방법
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9096541B2 (en) 2012-03-29 2015-08-04 Oklahoma Medical Research Foundation Inhibition of memapsin 1 cleavage in the treatment of diabetes
WO2013171167A1 (fr) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh Dérivé de xanthine en tant qu'inhibiteur de dpp-4 pour l'utilisation dans le traitement de troubles associés aux podocytes et/ou un syndrome néphrotique
WO2013174767A1 (fr) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
EP4233840A3 (fr) 2016-06-10 2023-10-18 Boehringer Ingelheim International GmbH Combinaisons de linagliptine et de metformine
JP2022548214A (ja) 2019-09-17 2022-11-17 ノバルティス アーゲー ビルダグリプチンとメトホルミンとの組み合わせ療法
US20220160619A1 (en) * 2020-11-25 2022-05-26 Complete Medical Solutions, Llc Effervescent Drug Formulations

Family Cites Families (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
US5543396A (en) 1994-04-28 1996-08-06 Georgia Tech Research Corp. Proline phosphonate derivatives
DE122010000020I1 (de) 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
WO1998018763A1 (fr) 1996-10-25 1998-05-07 Tanabe Seiyaku Co., Ltd. Derives de tetrahydroisoquinoline
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
CA2310400C (fr) 1997-11-18 2008-02-19 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Substance physiologiquement active, la sulphostine, procede de fabrication et utilisation
EP2823812A1 (fr) 1998-02-02 2015-01-14 Trustees Of Tufts College Inhibiteurs de dipeptidylpeptidase-IV pour leur utilisation dans le traitement du diabète de type II
JP2002506075A (ja) 1998-03-09 2002-02-26 フォンダテッヒ・ベネルクス・ナムローゼ・フェンノートシャップ セリンペプチダーゼ調節剤
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
PT1084129E (pt) 1998-06-05 2003-06-30 Point Therapeutics Inc Compostos de boroprolina ciclica
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
AU3960400A (en) * 1999-03-05 2000-09-28 Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv
WO2001034594A1 (fr) 1999-11-12 2001-05-17 Guilford Pharmaceuticals, Inc. Inhibiteurs de la dipeptidyl peptidase iv; methodes de fabrication et d'utilisation desdits inhibiteurs
GB9928330D0 (en) 1999-11-30 2000-01-26 Ferring Bv Novel antidiabetic agents
BRPI0107715B8 (pt) 2000-01-21 2021-05-25 Novartis Ag produto farmacêutico compreendendo um inibidor de dipeptidilpeptidase-iv e metformina, bem como usos do dito produto farmacêutico e do inibidor de dipeptidilpeptidase-iv
EP1254113A1 (fr) 2000-01-24 2002-11-06 Novo Nordisk A/S 2-cyanopyroles et -pyrrolines a substitution n inhibant l'enzyme dpp-iv
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
EP2266665B1 (fr) 2000-03-31 2016-05-11 Royalty Pharma Collection Trust Méthode pour l'amélioration de l'activité des céllules d' îlôts de Langerhans dans la diabète et son prévention
GB0010183D0 (en) 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
GB0010188D0 (en) 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
TW583185B (en) 2000-06-13 2004-04-11 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same
GB0014969D0 (en) 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
AU6895801A (en) 2000-07-04 2002-01-14 Novo Nordisk As Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv
AU2001278988A1 (en) 2000-07-21 2002-02-05 John F. Corcoran Intermodal container pallet
AU7775401A (en) 2000-08-10 2002-02-25 Welfide Corp Proline derivatives and use thereof as drugs
AU2001294197C1 (en) 2000-10-06 2005-05-19 Tanabe Seiyaku Co., Ltd. Aliphatic nitrogenous five-membered ring compounds
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
CA2433090A1 (fr) 2000-12-27 2002-07-04 Kyowa Hakko Kogyo Co., Ltd. Inhibiteur de dipeptidyl peptidase iv
WO2002053548A1 (fr) 2000-12-27 2002-07-11 Banyu Pharmaceutical Co.,Ltd. Derives de la benzothiazepine
CA2437492A1 (fr) 2001-02-02 2002-08-15 Yoshihiro Banno Composes heterocycliques condenses
WO2002066627A1 (fr) 2001-02-16 2002-08-29 Bayer Aktiengesellschaft Regulation de la dipeptidyle peptidase 8 humaine
ATE353900T1 (de) 2001-02-24 2007-03-15 Boehringer Ingelheim Pharma Xanthinderivate, deren herstellung und deren verwendung als arzneimittel
WO2002067918A1 (fr) 2001-02-27 2002-09-06 Banyu Pharmaceutical Co., Ltd. Nouveau derive de diallylmethylamine
JP2002265439A (ja) 2001-03-08 2002-09-18 Mitsubishi Pharma Corp シアノピロリジン誘導体およびその医薬用途
DE60226723D1 (de) 2001-03-27 2008-07-03 Merck & Co Inc Dipeptidylpeptidase-hemmer für die behandlung oder prävention von diabetes
FR2822826B1 (fr) 2001-03-28 2003-05-09 Servier Lab Nouveaux derives sulfonyles d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB0109146D0 (en) 2001-04-11 2001-05-30 Ferring Bv Treatment of type 2 diabetes
US6573287B2 (en) 2001-04-12 2003-06-03 Bristo-Myers Squibb Company 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
FR2824825B1 (fr) 2001-05-15 2005-05-06 Servier Lab Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20030060494A1 (en) 2001-05-18 2003-03-27 Nobuyuki Yasuda Pharmaceutical use of N-carbamoylazole derivatives
SE523510C2 (sv) 2001-05-18 2004-04-27 Jan G Faeger Förfarande för att fastställa en varelses position och/eller orientering i förhållande till en omgivning
CA2450475A1 (fr) 2001-06-20 2003-01-03 Linda Brockunier Inhibiteurs de dipeptidyl peptidase utilises dans le traitement du diabete
GB0115517D0 (en) 2001-06-25 2001-08-15 Ferring Bv Novel antidiabetic agents
CN1723196A (zh) 2001-06-27 2006-01-18 史密丝克莱恩比彻姆公司 作为二肽酶抑制剂的氟代吡咯烷
DE10150203A1 (de) 2001-10-12 2003-04-17 Probiodrug Ag Peptidylketone als Inhibitoren der DPIV
WO2003002530A2 (fr) 2001-06-27 2003-01-09 Smithkline Beecham Corporation Pyrrolidines servant d'inhibiteurs de dipeptidyl peptidase
US20030005443A1 (en) 2001-06-27 2003-01-02 Karin Axelsson EPG having PIP window history and sample view functionality
WO2003002596A2 (fr) 2001-06-27 2003-01-09 Probiodrug Ag Nouvelle utilisation d'inhibiteurs de la dipeptidyl peptidase iv
ES2291477T3 (es) 2001-06-27 2008-03-01 Smithkline Beecham Corporation Fluoropirrolidinas como inhibidores de dipeptidil peptidasa.
WO2003003250A1 (fr) 2001-06-28 2003-01-09 Hywire Ltd. Memoire adressable par son contenu constituee de plages
ATE388951T1 (de) 2001-07-03 2008-03-15 Novo Nordisk As Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
JP2005509603A (ja) 2001-09-19 2005-04-14 ノボ　ノルディスク　アクティーゼルスカブ Ｄｐｐ−ｉｖ酵素の阻害剤であるヘテロ環化合物
IL160917A0 (en) 2001-10-18 2004-08-31 Bristol Myers Squibb Co Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
GB0125446D0 (en) 2001-10-23 2001-12-12 Ferring Bv Novel anti-diabetic agents
GB0125445D0 (en) 2001-10-23 2001-12-12 Ferring Bv Protease Inhibitors
US6861440B2 (en) 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
AU2002360732A1 (en) 2001-12-26 2003-07-24 Guilford Pharmaceuticals Change inhibitors of dipeptidyl peptidase iv
US6727261B2 (en) 2001-12-27 2004-04-27 Hoffman-La Roche Inc. Pyrido[2,1-A]Isoquinoline derivatives
EP1496877B1 (fr) 2002-01-11 2008-10-01 Novo Nordisk A/S Methode et composition permettant de traiter le diabete, l'hypertension, l'insuffisance cardiaque chronique et les troubles de retention de fluide
KR100618752B1 (ko) 2002-02-13 2006-08-31 에프. 호프만-라 로슈 아게 신규한 피리딘- 및 퀴놀린-유도체
JP4359146B2 (ja) 2002-02-13 2009-11-04 エフ．ホフマン−ラ ロシュ アーゲー 新規なピリジン−およびピリミジン−誘導体
EP1338595B1 (fr) 2002-02-25 2006-05-03 Eisai Co., Ltd. Dérivés de Xanthines servant d'inhibiteurs de DPP-IV
HUP0200849A2 (hu) 2002-03-06 2004-08-30 Sanofi-Synthelabo N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
CN1633420A (zh) 2002-04-08 2005-06-29 托伦脱药品有限公司 噻唑烷－4－腈和类似物以及它们作为二肽基－肽酶抑制剂的用途
JP2003300977A (ja) 2002-04-10 2003-10-21 Sumitomo Pharmaceut Co Ltd キサンチン誘導体
JP2005531540A (ja) 2002-04-30 2005-10-20 トラスティーズ・オブ・タフツ・カレッジ セリンプロテアーゼ阻害剤のスマートプロドラッグ
JP2005533771A (ja) 2002-06-04 2005-11-10 ファイザー・プロダクツ・インク ジペプチジルペプチダーゼｉｖ阻害剤としてのフッ素化環式アミド
AU2003233010A1 (en) 2002-06-04 2003-12-19 Pfizer Products Inc. Process for the preparation of 3,3,4,4-tetrafluoropyrrolidine and derivatives thereof
RU2297418C9 (ru) 2002-06-06 2009-01-27 Эйсай Ко., Лтд. Новые конденсированные производные имидазола, ингибитор дипептидилпептидазы iv, фармацевтическая композиция, способ лечения и применение на их основе
HUP0202001A2 (hu) 2002-06-14 2005-08-29 Sanofi-Aventis DDP-IV gátló hatású azabiciklooktán- és nonánszármazékok
WO2004016840A1 (fr) 2002-08-13 2004-02-26 Kanebo, Ltd. Produit fonctionnel, poudre fine fonctionnelle utilisable lors de la production d'un tel produit, procede de production d'un produit fonctionnel
TW200404796A (en) 2002-08-19 2004-04-01 Ono Pharmaceutical Co Nitrogen-containing compound
CA2496249C (fr) 2002-08-21 2012-01-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-amino-piperidin-1-yl]-xanthines, leur production et leur utilisation comme medicament
DE10238477A1 (de) 2002-08-22 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Purinderivate, deren Herstellung und deren Verwendung als Arzneimittel
AU2003262059A1 (en) 2002-09-11 2004-04-30 Takeda Pharmaceutical Company Limited Sustained release preparation
EP1560811B9 (fr) 2002-09-19 2008-03-05 Abbott Laboratories Compositions pharmaceutiques utiles comme inhibiteurs de la peptidase-iv dipeptidyl (dpp-iv)
AU2003269850A1 (en) 2002-10-08 2004-05-04 Novo Nordisk A/S Hemisuccinate salts of heterocyclic dpp-iv inhibitors
DE60320008T2 (de) 2002-10-18 2009-06-18 Merck & Co., Inc. Heterozyklische beta-aminoverbindungen als inhibitoren des dipeptidylpeptidase zur behandlung bzw. prevention von diabetes
ES2344057T3 (es) 2002-10-23 2010-08-17 Bristol-Myers Squibb Company Inhibidores de la dipeptidil peptidasa iv basados en nitrilos de glicina.
AU2003286776A1 (en) 2002-10-30 2004-06-07 Guilford Pharmaceuticals Inc. Novel inhibitors of dipeptidyl peptidase iv
WO2004043940A1 (fr) 2002-11-07 2004-05-27 Merck & Co., Inc. Derives de phenylalanine utilises comme inhibiteurs de la dipeptidyl peptidase dans le traitement ou la prevention du diabete
EP1565437A1 (fr) 2002-11-18 2005-08-24 Pfizer Products Inc. Amides cycliques fluor s inhibant la dipeptidyl peptidase iv
DE10254304A1 (de) 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
AU2002952946A0 (en) 2002-11-27 2002-12-12 Fujisawa Pharmaceutical Co., Ltd. Dpp-iv inhibitor
UY28103A1 (es) 2002-12-03 2004-06-30 Boehringer Ingelheim Pharma Nuevas imidazo-piridinonas sustituidas, su preparación y su empleo como medicacmentos
AU2003297564A1 (en) 2002-12-04 2004-06-23 Merck & Co., Inc. Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US7420079B2 (en) 2002-12-09 2008-09-02 Bristol-Myers Squibb Company Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof
EP1624874B1 (fr) 2003-05-14 2009-11-04 Merck & Co., Inc. Derives d'acide 3-amino-4-phenylbutanoique en tant qu'inhibiteurs de dipeptidyl peptidase dans le cadre du traitement ou de la prevention du diabete
JP4579239B2 (ja) 2003-06-17 2010-11-10 メルク・シャープ・エンド・ドーム・コーポレイション 糖尿病の治療または予防するためのジペプチジルペプチダーゼ阻害剤としてのシクロヘキシルグリシン誘導体
DE10333935A1 (de) 2003-07-25 2005-02-24 Aventis Pharma Deutschland Gmbh Neue bicyclische Cyanoheterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
PE20050249A1 (es) 2003-07-25 2005-06-01 Aventis Pharma Gmbh Nuevas cianopirrolididas y procedimiento para su preparacion como medicamentos
US20050026881A1 (en) 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease
AU2004261243A1 (en) 2003-07-31 2005-02-10 3M Innovative Properties Company Bioactive compositions comprising triazines
US6995183B2 (en) 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
BRPI0413452A (pt) 2003-08-13 2006-10-17 Takeda Pharmaceutical composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv
WO2005019168A2 (fr) 2003-08-20 2005-03-03 Pfizer Products Inc. Derives fluores de lysine en tant qu'inhibiteurs de la dipeptidylpeptidase iv
BRPI0413204A (pt) * 2003-09-02 2006-10-03 Prosidion Ltd terapia de combinação para controle glicêmico
US7790734B2 (en) 2003-09-08 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20050065144A1 (en) 2003-09-08 2005-03-24 Syrrx, Inc. Dipeptidyl peptidase inhibitors
WO2005025554A2 (fr) 2003-09-09 2005-03-24 Japan Tobacco Inc. Inhibiteur de la dipeptidylpeptidase iv
DE10348022A1 (de) 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
GB0324236D0 (en) 2003-10-16 2003-11-19 Astrazeneca Ab Chemical compounds
TW200519105A (en) 2003-10-20 2005-06-16 Lg Life Science Ltd Novel inhibitors of DPP-IV, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent
PE20050444A1 (es) 2003-10-31 2005-08-09 Takeda Pharmaceutical Compuestos de piridina como inhibidores de la peptidasa
TW200528440A (en) 2003-10-31 2005-09-01 Fujisawa Pharmaceutical Co 2-cyanopyrrolidinecarboxamide compound
US7238683B2 (en) 2003-11-04 2007-07-03 Merck & Co., Inc. Fused phenylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
KR20070054762A (ko) 2003-11-12 2007-05-29 페노믹스 코포레이션 헤테로시클릭 보론산 화합물
JPWO2005051949A1 (ja) 2003-11-26 2007-06-21 住友製薬株式会社 新規縮合イミダゾール誘導体
DE10355304A1 (de) 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1541143A1 (fr) 2003-12-09 2005-06-15 Graffinity Pharmaceuticals Aktiengesellschaft Inhibiteurs de dpp-iv
EP1541148A1 (fr) 2003-12-09 2005-06-15 Graffinity Pharmaceuticals Aktiengesellschaft Inhibiteurs de dpp-iv
US7504423B2 (en) 2003-12-11 2009-03-17 Mitsubishi Tanabe Pharma Corporation α-amino acid derivatives and use thereof as medicines
WO2005058849A1 (fr) 2003-12-15 2005-06-30 Glenmark Pharmaceuticals Ltd. Nouveaux inhibiteurs de dipeptidyle peptidase iv, leur procede de preparation et compositions les contenant
DE10359098A1 (de) 2003-12-17 2005-07-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-(Piperazin-1-yl)- und 2-([1,4]Diazepan-1-yl)-imidazo[4,5-d]pyridazin-4-one, deren Herstellung und deren Verwendung als Arzneimittel
DE10360835A1 (de) 2003-12-23 2005-07-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel
WO2005073186A1 (fr) 2004-01-29 2005-08-11 Ono Pharmaceutical Co., Ltd. Dérivés de pyrrolidine
WO2005075426A1 (fr) 2004-02-03 2005-08-18 Glenmark Pharmaceuticals Ltd. Nouveaux inhibiteurs de dipeptidyle peptidase iv, leur procedes de preparation et compositions en comportant
US7754757B2 (en) 2004-02-05 2010-07-13 Kyorin Pharmaceutical Co., Ltd. Bicycloester derivative
EP2119717B1 (fr) 2004-02-18 2018-01-17 Boehringer Ingelheim International GmbH 8-[3-amino-pipéridine-1-yl]-xanthine, leur fabrication et leur utilisation en tant que complexe DDP IV
AU2005212073B2 (en) 2004-02-18 2010-07-08 Kyorin Pharmaceutical Co., Ltd. Bicyclic amide derivatives
DE102004009039A1 (de) 2004-02-23 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
JP4781347B2 (ja) 2004-02-23 2011-09-28 トラスティーズ オブ タフツ カレッジ グルコース代謝を制御するためのペプチジルペプチダーゼｉｖ阻害剤
EP1719757B1 (fr) 2004-02-27 2013-10-09 Kyorin Pharmaceutical Co., Ltd. Derive bicyclo
KR100552043B1 (ko) 2004-02-28 2006-02-20 주식회사종근당 푸마질롤 유도체를 포함하는 비만치료용 조성물
EP1593671A1 (fr) 2004-03-05 2005-11-09 Graffinity Pharmaceuticals AG Inhibiteurs de la DPP-IV
AU2005221678B2 (en) 2004-03-09 2008-10-09 National Health Research Institutes Pyrrolidine compounds
DE102004012366A1 (de) 2004-03-13 2005-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Imidazopyridazindione, deren Herstellung und deren Verwendung als Arzneimittel
AU2004318013B8 (en) 2004-03-15 2011-10-06 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2005095339A1 (fr) 2004-03-31 2005-10-13 Pfizer Products Inc. Dicyanopyrrolidines inhibiteurs de la dipeptidyl peptidase iv
WO2005097798A1 (fr) 2004-04-10 2005-10-20 Boehringer Ingelheim International Gmbh Nouvelles 2-amino-imidazo[4,5-d]pyridazin-4-ones et 2-amino-imidazo[4,5-c]pyridin-4-ones, leur production et leur utilisation comme medicaments
WO2005100334A1 (fr) 2004-04-14 2005-10-27 Pfizer Products Inc. Inhibiteurs de dipeptidyl peptidase-iv
TW200604167A (en) 2004-04-27 2006-02-01 Astellas Pharma Inc Pyrrolidine derivatives
EP1756074A4 (fr) 2004-05-04 2010-05-19 Merck Sharp & Dohme Derives de 1,2,4-oxadiazole en tant qu'inhibiteurs de la dipeptidylpeptidase-iv dans le traitement ou la prevention de diabetes
EP1598341A1 (fr) 2004-05-21 2005-11-23 Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft Inhibiteurs de DPP-IV
TWI354569B (en) * 2004-05-28 2011-12-21 Bristol Myers Squibb Co Coated tablet formulation and method
WO2005118555A1 (fr) 2004-06-04 2005-12-15 Takeda Pharmaceutical Company Limited Inhibiteurs de la dipeptidyl peptidase
EP1604662A1 (fr) 2004-06-08 2005-12-14 Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft Derivés de la benzyl amine du acide carboxylique (2R) de la 1-[(3R)-Amino-4-(2-fluoro-phenyl)-butyl]-pyrrolidine et composés similaires pour l'utilisation comme inhibiteurs de la peptidase dipeptidyl IV (DPP-IV) pour le traitement de la diabetes mellitus de type 2

Also Published As

Publication number Publication date
JP2013227337A (ja) 2013-11-07
CA2634379C (fr) 2014-05-20
EP1965783A1 (fr) 2008-09-10
US20160279105A1 (en) 2016-09-29
EP1965783B1 (fr) 2013-06-19
WO2007072083A1 (fr) 2007-06-28
AU2006327974B2 (en) 2012-10-04
BRPI0620450A2 (pt) 2011-11-08
DK1965783T3 (da) 2013-08-05
PT1965783E (pt) 2013-08-27
SG186610A1 (en) 2013-01-30
US20140051734A1 (en) 2014-02-20
MX2008008250A (es) 2008-11-06
CN101365434A (zh) 2009-02-11
CY1114401T1 (el) 2016-08-31
UA100111C2 (ru) 2012-11-26
KR20080080220A (ko) 2008-09-02
JP2009520801A (ja) 2009-05-28
AU2006327974A1 (en) 2007-06-28
HK1121074A1 (en) 2009-04-17
ZA200806200B (en) 2009-04-29
EA200801538A1 (ru) 2008-12-30
ES2427822T3 (es) 2013-11-04
GB0526291D0 (en) 2006-02-01
IL192257A0 (en) 2009-02-11
US20100216800A1 (en) 2010-08-26
EA017084B1 (ru) 2012-09-28
CA2634379A1 (fr) 2007-06-28
PL1965783T3 (pl) 2013-11-29
NO20082790L (no) 2008-09-16
RS52942B (en) 2014-02-28
NZ569427A (en) 2011-11-25
SI1965783T1 (sl) 2013-10-30
HRP20130880T1 (hr) 2013-10-25

Similar Documents

Publication Publication Date Title
MA30085B1 (fr) Traitement du diabete de type 2 avec une association d'un inhibiteur de dpiv et de metformine ou d'une thiazolidinedione
MA32539B1 (fr) Traitement du diabète chez des patients pour lesquels une thérapie par la metformine n'est pas appropriée
BRPI0416628A (pt) uso de compostos orgánicos
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
TW200510349A (en) Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
MA29378B1 (fr) Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer
TW200609227A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
TNSN07063A1 (fr) Utilisations therapeutiques d'inhibiteurs de rtp801
MA27548A1 (fr) Inhibiteurs heterocycliques beta-amines de la dipeptidyl peptidase pour le traitement ou la prevention du diabete.
GB0318447D0 (en) Therapeutic agents
HK1070575A1 (en) Use of botulinum toxin for treating cardiovasculardiseases
MA30632B1 (fr) Anticorps humanisé
MA29836B1 (fr) Proteines de fusion avec l'albumine
MA29692B1 (fr) Derives de la xanthine en tant qu'agonistes selectifs du hm74a
UA85707C2 (ru) Бензоксазины для лечения заболеваний дыхательных путей
IS2517B (is) Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
JP2007534657A5 (fr)
MY141972A (en) Biaryloxymethylarenecarboxylic acids
TW200505418A (en) Phenacyl 2-hydroxy-3-diaminoalkanes
BR0210392A (pt) Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto
ATE371724T1 (de) Behandlung neurodegenerativer krankheiten
ATE392471T1 (de) Behandlung neurodegenerativer krankheiten durch verwendung von scd4-inhibitoren
MA31446B1 (fr) Inhibiteurs de raf pour le traitement du cancer de la thyroide
MA30432B1 (fr) Procede de traitement de l'hemochromatose hereditaire
MA56998B1 (fr) Traitement de symptômes induits par le cycle menstruel